126 related articles for article (PubMed ID: 15580312)
1. Alternative phospholipase D/mTOR survival signal in human breast cancer cells.
Chen Y; Rodrik V; Foster DA
Oncogene; 2005 Jan; 24(4):672-9. PubMed ID: 15580312
[TBL] [Abstract][Full Text] [Related]
2. Phospholipase D confers rapamycin resistance in human breast cancer cells.
Chen Y; Zheng Y; Foster DA
Oncogene; 2003 Jun; 22(25):3937-42. PubMed ID: 12813467
[TBL] [Abstract][Full Text] [Related]
3. Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D.
Hui L; Zheng Y; Yan Y; Bargonetti J; Foster DA
Oncogene; 2006 Nov; 25(55):7305-10. PubMed ID: 16785993
[TBL] [Abstract][Full Text] [Related]
4. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53.
Mungamuri SK; Yang X; Thor AD; Somasundaram K
Cancer Res; 2006 May; 66(9):4715-24. PubMed ID: 16651424
[TBL] [Abstract][Full Text] [Related]
5. Targeting mTOR-mediated survival signals in anticancer therapeutic strategies.
Foster DA
Expert Rev Anticancer Ther; 2004 Aug; 4(4):691-701. PubMed ID: 15270672
[TBL] [Abstract][Full Text] [Related]
6. Regulation of mTOR by phosphatidic acid?
Foster DA
Cancer Res; 2007 Jan; 67(1):1-4. PubMed ID: 17210675
[TBL] [Abstract][Full Text] [Related]
7. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival.
Troussard AA; McDonald PC; Wederell ED; Mawji NM; Filipenko NR; Gelmon KA; Kucab JE; Dunn SE; Emerman JT; Bally MB; Dedhar S
Cancer Res; 2006 Jan; 66(1):393-403. PubMed ID: 16397254
[TBL] [Abstract][Full Text] [Related]
8. Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.
Crowder RJ; Ellis MJ
Breast Cancer Res; 2005; 7(5):212-4. PubMed ID: 16168140
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
Chang SB; Miron P; Miron A; Iglehart JD
J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.
Del Bufalo D; Ciuffreda L; Trisciuoglio D; Desideri M; Cognetti F; Zupi G; Milella M
Cancer Res; 2006 Jun; 66(11):5549-54. PubMed ID: 16740688
[TBL] [Abstract][Full Text] [Related]
11. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway.
Pervin S; Singh R; Hernandez E; Wu G; Chaudhuri G
Cancer Res; 2007 Jan; 67(1):289-99. PubMed ID: 17210710
[TBL] [Abstract][Full Text] [Related]
13. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.
Klos KS; Wyszomierski SL; Sun M; Tan M; Zhou X; Li P; Yang W; Yin G; Hittelman WN; Yu D
Cancer Res; 2006 Feb; 66(4):2028-37. PubMed ID: 16489002
[TBL] [Abstract][Full Text] [Related]
14. From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy.
Georgakis GV; Younes A
Expert Rev Anticancer Ther; 2006 Jan; 6(1):131-40. PubMed ID: 16375650
[TBL] [Abstract][Full Text] [Related]
15. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
16. Defective TGF-beta signaling sensitizes human cancer cells to rapamycin.
Gadir N; Jackson DN; Lee E; Foster DA
Oncogene; 2008 Feb; 27(8):1055-62. PubMed ID: 17700525
[TBL] [Abstract][Full Text] [Related]
17. Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.
Manuvakhova M; Thottassery JV; Hays S; Qu Z; Rentz SS; Westbrook L; Kern FG
Oncogene; 2006 Sep; 25(44):6003-14. PubMed ID: 16682955
[TBL] [Abstract][Full Text] [Related]
18. Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc.
Rodrik V; Zheng Y; Harrow F; Chen Y; Foster DA
Mol Cell Biol; 2005 Sep; 25(17):7917-25. PubMed ID: 16107734
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Generali D; Fox SB; Brizzi MP; Allevi G; Bonardi S; Aguggini S; Milani M; Bersiga A; Campo L; Dionisio R; Vergoni F; Giardini R; Dogliotti L; Bottini A; Harris AL; Berruti A
Clin Cancer Res; 2008 May; 14(9):2673-80. PubMed ID: 18451231
[TBL] [Abstract][Full Text] [Related]
20. IGF-1 activates hEAG K(+) channels through an Akt-dependent signaling pathway in breast cancer cells: role in cell proliferation.
Borowiec AS; Hague F; Harir N; Guénin S; Guerineau F; Gouilleux F; Roudbaraki M; Lassoued K; Ouadid-Ahidouch H
J Cell Physiol; 2007 Sep; 212(3):690-701. PubMed ID: 17520698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
